Technical Analysis for AFMD - Affimed Therapeutics B.V.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Historical AFMD trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Slingshot Bullish | Bullish Swing Setup | -2.00% | |
| Calm After Storm | Range Contraction | -2.00% | |
| Upper Bollinger Band Walk | Strength | -2.00% | |
| Earnings Movers | Other | -2.00% | |
| Multiple of Ten Bearish | Other | -2.00% | |
| Wide Bands | Range Expansion | -2.00% | |
| New 52 Week Closing High | Bullish | -10.06% | |
| New 52 Week High | Strength | -10.06% | |
| Upper Bollinger Band Walk | Strength | -10.06% | |
| Multiple of Ten Bullish | Other | -10.06% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 3% | about 2 hours ago |
| Down 2 % | about 2 hours ago |
| Down 1% | about 2 hours ago |
| 3x Volume Pace | 1 day ago |
| Down 10% | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 04/15/2021
Affimed Therapeutics B.V. Description
Affimed Therapeutics B.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. The company's product candidates also comprise AFM11, a T-cell TandAb for the treatment of certain CD19+ B-cell malignancies, including non-hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Affimed Therapeutics B.V. has license agreements with Amphivena Therapeutics, Inc. to develop a product candidate for hematologic malignancies; and Xoma Ireland Limited to conduct research on immunoglobulins. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Development Solid Tumors Monoclonal Antibodies Lymphoma Prostate Cancer Blastoma Immunotherapies Glioblastoma Hematologic Malignancies Epidermal Growth Factor Receptor Head And Neck Cancer Chronic Lymphocytic Leukemia Lymphocytic Leukemia CD19 Hodgkin Lymphoma Natural Killer Cell Tumors Of The Hematopoietic And Lymphoid Tissues Non Hodgkin Lymphoma Cd30 Entospletinib
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.78 |
| 52 Week Low | 1.88 |
| Average Volume | 3,725,253 |
| 200-Day Moving Average | 5.17 |
| 50-Day Moving Average | 7.04 |
| 20-Day Moving Average | 8.39 |
| 10-Day Moving Average | 8.89 |
| Average True Range | 0.77 |
| ADX | 38.23 |
| +DI | 34.92 |
| -DI | 12.36 |
| Chandelier Exit (Long, 3 ATRs ) | 8.46 |
| Chandelier Exit (Short, 3 ATRs ) | 9.46 |
| Upper Bollinger Band | 10.15 |
| Lower Bollinger Band | 6.64 |
| Percent B (%b) | 0.81 |
| BandWidth | 41.88 |
| MACD Line | 0.75 |
| MACD Signal Line | 0.60 |
| MACD Histogram | 0.1528 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.97 | ||||
| Resistance 3 (R3) | 10.99 | 10.52 | 10.72 | ||
| Resistance 2 (R2) | 10.52 | 10.14 | 10.51 | 10.63 | |
| Resistance 1 (R1) | 10.00 | 9.91 | 9.77 | 9.98 | 10.55 |
| Pivot Point | 9.53 | 9.53 | 9.41 | 9.52 | 9.53 |
| Support 1 (S1) | 9.01 | 9.15 | 8.78 | 8.99 | 8.41 |
| Support 2 (S2) | 8.54 | 8.92 | 8.53 | 8.33 | |
| Support 3 (S3) | 8.02 | 8.54 | 8.24 | ||
| Support 4 (S4) | 8.00 |
